Journal
PLOS GENETICS
Volume 11, Issue 7, Pages -Publisher
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pgen.1005305
Keywords
-
Categories
Funding
- UCSF Cancer Center
- UCSF Academic Senate
- Damon Runyon Cancer Research Foundation [DRG-109-10]
- NIH NCI [5K08CA172288, R01-CA170447]
- NIH NIGMS MARC [T34-GM008574]
- American Cancer Society Postdoctoral Fellowship
- Agricultural Research Foundation of Oregon
- John Fryer Salmon Disease Laboratory of the Department of Microbiology at Oregon State University
- V-Foundation Scholar Award
- UCSF Liver Center [NIH P30DK026743]
- NIH [DK60322]
- Packard Foundation
- Diabetes Research Center (DRC) [NIH P30 DK063720]
Ask authors/readers for more resources
Hepatocellular carcinoma (HCC) is one of the most lethal human cancers. The search for targeted treatments has been hampered by the lack of relevant animal models for the genetically diverse subsets of HCC, including the 20-40% of HCCs that are defined by activating mutations in the gene encoding beta-catenin. To address this chemotherapeutic challenge, we created and characterized transgenic zebrafish expressing hepatocyte-specific activated beta-catenin. By 2 months post fertilization (mpf), 33% of transgenic zebrafish developed HCC in their livers, and 78% and 80% of transgenic zebrafish showed HCC at 6 and 12 mpf, respectively. As expected for a malignant process, transgenic zebrafish showed significantly decreased mean adult survival compared to non-transgenic control siblings. Using this novel transgenic model, we screened for druggable pathways that mediate beta-catenin induced liver growth and identified two c-Jun N-terminal kinase (JNK) inhibitors and two antidepressants (one tricyclic antidepressant, amitriptyline, and one selective serotonin reuptake inhibitor) that suppressed this phenotype. We further found that activated beta-catenin was associated with JNK pathway hyperactivation in zebrafish and in human HCC. In zebrafish larvae, JNK inhibition decreased liver size specifically in the presence of activated beta-catenin. The beta-catenin-specific growth-inhibitory effect of targeting JNK was conserved in human liver cancer cells. Our other class of hits, antidepressants, has been used in patient treatment for decades, raising the exciting possibility that these drugs could potentially be repurposed for cancer treatment. In support of this proposal, we found that amitriptyline decreased tumor burden in a mouse HCC model. Our studies implicate JNK inhibitors and antidepressants as potential therapeutics for beta-catenin-induced liver tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available